相关实验视频
Updated: Jul 18, 2025

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
Published on: April 7, 2023
简氏激酶抑制剂用于治疗牛皮关节炎
Sanchita Raychaudhuri1, Ruchi Jayeshbhai Shah2, Smriti K Raychaudhuri1
1Department of Dermatology, School of Medicine, University of California, Davis, California.
简氏激酶 (JAK) 抑制剂为那些不对现有疗法做出反应或不耐受现有疗法的牛皮关节炎 (PsA) 患者提供了新的治疗选择. 本综述涵盖已批准和正在开发的JAK/STAT和TYK2抑制剂,用于治疗PsA.
科学领域:
- 类风湿病学 类风湿病学
- 免疫学 免疫学 免疫学
- 皮肤病学 皮肤病学
背景情况:
- 牛皮病性关节炎 (PsA) 是一种系统性炎症性疾病,影响关节,皮肤,指甲和内.
- 目前针对PsA的治疗方法针对特定的临床领域,但具有局限性,包括不响应和不良影响.
- 简氏激酶 (JAK) /STAT信号通路在PsA的炎症过程中起着至关重要的作用.
研究的目的:
- 审查目前已批准的JAK抑制剂用于PSA治疗.
- 讨论新兴的JAK抑制剂和TYK2抑制剂在PSA的开发中.
- 突出JAK/STAT抑制在治疗PSA中的潜力.
主要方法:
- 对PSA的已批准和正在研究的JAK抑制剂的文献综述.
- 对临床试验数据和作用机制的分析.
- 讨论涉及JAK/STAT和TYK2抑制的治疗策略.
主要成果:
- 几种JAK抑制剂已被批准用于PsA,为非响应者提供了替代品.
- 新的JAK抑制剂和TYK2抑制剂正处于临床开发的各个阶段.
- 这些向疗法在解决多个PSA领域方面表现有前途.
结论:
- JAK/STAT和TYK2抑制剂代表了PsA治疗的重大进展.
- 这些药物为没有满足需求的患者提供了新的治疗途径.
- 进一步的研究将阐明这些新型药物的长期疗效和安全性.
相关概念视频
The JAK-STAT Signaling Pathway
PI3K/mTOR/AKT Signaling Pathway
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
cAMP-dependent Protein Kinase Pathways
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...

